Ovid Therapeutics - UBS Global Biopharma Conference - OVID THERAPEUTICS INC
Good afternoon, everyone. My name is Aiden Bracken. I am a director on the U.S.-based UBS Biotechnology Investment Banking team. Thank you for everyone who has presented today and attending our inaugural 2026 Biopharma Conference here at the Rosewood. It's my pleasure to introduce Ovid Therapeutics and the president and CEO, Meg Alexander. Thank you very much, Aiden. Good afternoon everyone. It's My pleasure to give you an update today on our company, Ovid therapeutics. At Ovid, we are dedicated to pioneering better and gentler medicines for brain diseases. Ovid is a publicly traded company, and we will be making forward-looking statements today. But I'm excited to tell you about Ovid not just about the company we are, but because this is a really important time for the company. And I would say at this point we're in the playoffs and maybe headed to the Super Bowl. Perhaps not the right analogy for the Brits, but we're an American company. And our strategy at Ovid is really what you see in front of you. Several years ago, we looked out at the field of neurology and neuropsychiatry, and it was a little depressing because when you looked at pipelines from the preclinics straight through to marketed medicines, we could see that essentially drug development for the CNS was what I would call a sea of sameness, where many of our peers in the space were going after targets that were already known with mechanisms of action that had slightly better pharmacology, or chemistry. And that's important. We all want better medicines, but they weren't going to be a step change for patients. So we embarked upon a very deliberate strategy to build and curate our pipeline at Ovid. Andthat's really what you see in front of you. We wanted to go after fundamental targets that help regulate the balance of excitation and inhibition of neurons in the brain, and that we thought would have potentially broad potential in so doing. Wewanted to go with differentiated mechanisms of action, because again, with a sea of sameness, we wanted to really try to bring a step change for patients. And we thought this might also translate into bigger commercial opportunities if we're able to differentiate our assets. And then finally, we were going after small molecule targets, because at the end of the day, we want medicines that are easy for patients to take. And it took some time, but now we have a fully integrated pipeline, and we have actually four major readouts coming in the next six and 12 months, and it's very exciting. And it's happening across this pipeline that you see in front of you. So as I said, it's a busy time, and we have a very replete pipeline. And I'll start at the top of the pipeline, and then we'll go down to the bottom. But essentially, we have very exciting mechanisms of action that work different ways on GABA, the main breaking, basically, system in the brain, or the main inhibitory neurotransmitter in the brain. And I'll start with these basically programs that are sort of a greenish teal. And these are multiple proof of signal and proof of concept studies that are running for what is our program called OV329, which is a program, essentially the mechanism inhibits the main enzyme that eats GABA or catabolizes GABA, again, the main inhibitory neurotransmitter of the brain, and we're embarking on multiple epilepsy studies, including a phase two study that's running right now and a photosensitivity study, which is a very interesting translational study that it's going to read out in just a couple months from now that should significantly de-risk the doses that we're taking into our pivotal studies. But why this is an exciting program is this mechanism has been validated before, but it was essentially validated by a very crude first-generation drug that had a lot of tolerability, safety baggage that we've subsequently unpacked. We now know that we have a safe version of this mechanism. So we're taking it into focal epilepsy in adults, but it has broad potential therapeutic utility. So, we've also created a pediatric formulation of this program of E329, and we're really excited to now unlock its potentials in some very severe forms of pediatric epilepsy where we know this mechanism should work, and that's seizures associated with tuberous sclerosis complex, as well as infantile spasms. And I'll talk a little bit more about that. But those programs are underway and moving into the clinic in the pediatric instance. Below that, these purple programs, is a very exciting portfolio of molecules that activate a target called KCC2. KCC1 stands for potassium chloride co-transporter 2. And KCC3 is the target in the brain that clinicians, large pharmaceutical companies have wanted to drug for two decades, but it's been extremely hard to drug. But now we've done it, and we have an oral KCC2 direct activator that's in the clinic and progressing well, and that is OV4071. And we've learned a lot about how to drug this target in the span of the last three to four years, where we've had to work through new questions and new challenges. And as a result, we have a discovery engine that sits underneath of it. And KCC2 is a much wanted target to drug because the therapeutic applicability of drugging this target is considered to be quite vast. No one has been able to prove it until recently. And now all of the pharmacodynamic work that we've done in animals is suggesting that drugging KCC3 may really be true. And we'll talk about the domains that includes, but everything from forms of psychosis to seizures, pain, anxiety, these are some of the therapeutic area domains that KCC2 has been linked to. And we now have a molecule and data that's suggesting that it is indeed this broad. It's a very exciting moment. But we'll start with OV329, which is our epilepsy acid. And epilepsy has been a busier field of late. And that's a good thing for patients. We've got better medicines starting to come to the fore. But amazingly, despite knowing about seizures and epilepsy truly for millennia, seizure drugs haven't gotten that much better. And what I mean by that is today, there's still so much unmet need, despite really good work by some of my peers and friends in the space. And what we don't have today is a drug that works really well to crush the seizures, that is safe and well-tolerated, doesn't make you feel poorly, and that's easy to use and works well in polypharmacy regimens. That sounds like a super vanilla profile, but in fact, nobody has been able to do that well yet. And 329 may actually be stacking up to be the holy grail in epilepsy. So with OV329, again, our epilepsy program, we know this is a validated mechanism for reducing seizures and a broad array of seizures. So if we're at the right dose, it should work. And it, by the way, works in more animal models for seizure than any seizure drug we've ever seen in development. It is rationally designed to be very potent, but also to have improved tolerability. So we're seeing at doses where we know we deliver inhibition or restoring the breaking system in the brain, it has better tolerability than any leisure medicine at this stage of development that has been trialed or that's even marketed. So it's quite encouraging, despite being early. And it should be very easy to use. It doesn't interact with other drugs. It's once daily. It doesn'T require titration. And it essentially would be a new mechanism of action for epilepsy because the first drug that tried to use this just had a lot of baggage, didn't work. So this is very exciting, and we think its potential is broad to take across a number of epilepsies. And why we have conviction is we're trying to essentially replace what was a very crude first-generation medicine that was marketed by a company called Lundbeck that worked to reduce seizures, but it brought a lot of baggage along with it. So if you see the slide behind me, you can see some of the epilepsies that this mechanism of action has previously been characterized in. And the seizure reduction is quite profound if you look across the different epilepses, both adult and pediatric. But the safety was a real barrier to this. The first-generation drug that we are subsequently replacing essentially preferentially partitioned in the eye and led to a form of irreversible blindness. So clearly that's not acceptable, right? Reducing seizures is urgent, it's an emergency of the brain. Making somebody blind simultaneously, not an okay trade-off. And beyond that, it had a lot of tolerability issues, sedation among other things. Whereas with OV329, it was rationally designed by the same medicinal chemist who invented Lyrica, who then subsequently made it his life's work to do a better version of this mechanism. And that's what 329 is. Because of the therapeutic index that we've been able to carve with this medicine, we know that OV329 at our planned clinical doses can increase more GABA, again, the main inhibitory neurotransmitter, both in the synapse and in the extrasynaptic region, creating a more inhibitory environment around the neuron, so calming the excitation down. whereas the first generation drug was so intolerable it couldn't do that it could only kind of blast levels of the main inhibitory neurotransmitter in the synapse which also can lead to sedation and some tolerability issues that i could get into the technical reasons as to why so we believe with this more comprehensive form of inhibition that our drug is delivering we may be able to be both more tolerable but potentially drive more anti-convulsant efficacy as well So this is very encouraging to us, and we're asking and answering the right questions in the clinical trials to know this now. And if we're right, the opportunity with 329 could be significant. So what you see in front of you is both the potential market and the opportunity in adult focal onset seizures as well as in pediatric epilepsies, including several of the developmental epileptic encephalopathies that this is a validated mechanism for. And what's very convenient for us is for 329, not only can we develop different formulations which helps from a pricing perspective but it's also very needed for these populations in infantile spasms and tuberous sclerosis complex seizures we're dealing with babies and children they can't take a fixtures pill they need a different type of formulation and we're pursuing basically a granule in a form of sachet so it can mix into food or formula things of that nature whereas adults in the focal epilepsy need a pill so this allows us to separate the two programs despite it being a similar mechanism of action, and to appropriately introduce them to the market, including pricing them separately. So significant opportunities, multi-billion dollar opportunities there. But a really important step that we had to leap over in order for us, but importantly the external world, to have conviction in 329 is, of course, that we weren't going to have the same ophthalmic safety issues that the first-generation drug had. So this meant a number of the killer experiments needing to be run, dedicated toxicology work for the eye, but essentially what we've been able to show and what this slide shows is we proved what independent research had shown, which is that this first generation drug, the compound specifically to that compound partitions and accumulates in the eye. We proved it. And at the same exposures for our drug, 329, we get into the tissue very quickly, but then we clear it and it's undetectable. So we don't have this type of accumulation that occurs. We also have a very different secondary pharmacology profile, which contributes to the toxicology that happened with that first-generation drug. And we can see when we go into the animals and we look in the eye, if you look in far right, that's the first- generation drug. The kind of little purple circles, which is the back of the eye and the retinal cells, they're not looking neat and tidy. And this is some of the degeneration that starts to happen. If you look in the middle of the page, that is a scaled therapeutic dose of our drug, OV329. The retina remains intact and healthy. And this is an example of many of the studies that we had to do over the last several years to differentiate the fact that our safety profile is very different. And the first generation's drug was idiosyncratic to that compound. In addition, I said that we have more seizure models supporting the efficacy, the potential efficacy of 329 than any seizure medicine has ever had. That's true. And don't worry, we're not going to walk you through all of them. But these were two meaningful ones. This is an infantile spasms model, which is one of our planned indications on the left with our drug. The right is a mesial temporal lobe epilepsy model, which is about as good a reproduction of focal seizures that you can get in an animal. In both cases, we've seen very profound rescue and seizure cessation associated with scaled doses of OV329. And I said before, it appears that maybe 329 could be the holy grail in the sense of it works, but it doesn't make you feel like crap. And that's certainly what we've see in humans. We've tested OV329 in about 100 humans to date, and the tolerability profile is very amenable to chronic use. So we saw a couple of adverse events, one case of sedation and drowsiness, a headache, but overall our planned clinical doses appear to be extremely well tolerated while also delivering inhibition in the brain. One of the things we do at Ovid is we try to ask the hard questions and the most important questions early in development to learn as much as we possibly can, make the best next choices as we proceed. One of the things that we did in our phase one program was we were able to replicate research that essentially had looked at that first generation drug, and using TMS, which is a form of electrophysiology, transcranial magnetic stimulation, among other things, we wereable to show that our drug, OV329, delivered cortical inhibition in the brain that in some cases matched but also exceeded or surpassed in a positive way the level of inhibition and the brain the therapeutic doses of the first generation drug that we're trying to replace did so basically we know if if the first gen drug delivered anti-convulsant effect with this level of innovation in the and we're beating that that's a pretty good sign that the clinical doses that we'RE taking into the studies now should work And that's the way much of the investment community felt because they gave us about $175 million to go do the next step. And that is what we are in the middle of doing now. So one of the questions that we are answering is again confirming anti-convulsant effect using a really neat translational approach called a photosensitivity model. And basically what this is, is there are humans who have a type of reflexive epilepsy to light. You may have heard of this from children going to sometimes the movies and having a seizure. right? That's actually what this is. But what we can do in a more responsible fashion is you can trial doses of drugs in these very rare population who have seizures when they're stimulated by a certain kind of light. And it allows you to see whether your drug is having an anticonvulsant effect at the doses you want to take into clinical trials. And we do this responsibly. They're all subclinical seizures. So we're not, you know, evoking a real clinical seizure in a human being. But this has been a very proven way of being able to confirm anticonvulsant dose. So we're doing this right now, and we will have a readout in the first quarter of next year, which we're very excited about. It's an open-label study, and we're trialing the planned clinical dose in our phase two, as well as a dose above and below that. So I think that will be really helpful information, should significantly de-risk the dose that we plan to take into pivotal studies, given that this is a drug that we believe will have potentially very broad therapeutic utility. And we're also running a phase two study all over the world in focal epilepsy. This is a busy space, but again, I think we have a very differentiated profile, even relative to some really good peers in epilepsy. And the nice thing with focal seizures and epilepsy is this is a very templated playbook for how to essentially develop a seizure medicine. Hard endpoints, we'll be looking primarily at reduction in seizures from monthly baseline, along with some secondary endpoints too. And we're in field doing this. We've got the regulatory clearances, and we're up and running the trial all over the world. We expect to read out in the second half of next year. So that's our epilepsy program with OV329. We're very excited by it, and I have huge excitement not just about what this may mean for adults, but also what this could mean for children who have very bad epilepsies. Some of these kids don't respond well to other seizure mechanisms. Meta-analysis has shown this well. And we may even be able to bend the poor neurodevelopmental outcomes that these babies and toddlers and children have by being able to treat with OV329 earlier and for longer. So that is the lead program in our pipeline. But we have what is potentially a transformative pipeline that sits below that and our KCC2 portfolio. Now, KCC1 is the target in the brain that clinicians and strategics have wanted to drug for the last 20 years. And the reason why is it's a very special target. Essentially, KCC2 is a master switch on neural hyperexcitability. And it's special for a few different reasons. One is it is essentially neuron-specific. What the transporter's job does is it balances potassium and chloride. And it essentially spits enough chloride out of a neuron for GABA, again, the braking system in the brain, to be inhibitory or hyperpolarizing. And if KCC2 is reduced in expression or dysfunctional, the breaking system in the brain can't work optimally. And we've seen this and identified it now across a whole host of different disease and disease symptoms. But because it's only in the neuron, or only in CNS rather, we don't run the risk of some of the same effects that are seen with other ion co-transporters, which are expressed in other tissue in the grain. And what's exciting about this is it's very hard to over-modulate. Like so many things in the brain, we're always kind of in this Goldilocks position of trying to get it just right. But KCC2, you actually can't get this neuron to pump out or this co-transporter to pump out too much chloride. So it's a more precise way of tuning GABA. And what all that means is that we see a tolerability profile that appears to be far more attractive than the typical CNS or psychiatric medicine. and I've pretty much explained the way that it works as I said it balances potassium and chloride and it may be finally a more precise way of tuning GABA in the brain and restoring excitatory inhibitory balance and as I've said it's been a field that it's a target that the field has wanted to drug for the better part of two decades no one was able to do it and the reason was why was a couple-fold. Primarily, just the chemistry of trying to drug and directly activate a transporter is hard. And it took us several years, and there was a number of challenges that we had to work through from medicinal chemistry to formulation. But now we've done it. And what is exciting to me and our team is we have a very promising molecule in the clinic right now that's proceeding through phase 1 trial. That's OV4071. And this is the first ever oral KCC2 direct activator. And this molecule is performing very well. We had a tool program before it that we learned a lot from. But when we got to OV 4071, its drug-like properties and activities was very exciting to us. And it's shown itself to potentially have very profound activity, truly possibly unlocking the value of drug in KCC2, which appears to be broad. So with OV4071, we know it has a very good tolerability profile. We have great safety margins for it. We haven't seen sedation associated with it. So back to that kind of sweet spot of not over-modulating GABA. It appears to me profoundly active. So beyond being very potent, we have now characterized as OV4071 and our tool program, in about 100 different pharmacology and pharmacodynamic studies. And what OV 4071 is consistently showing us is rapid, sustained, and profound activity in a number of therapeutic area domains. Our primary interest is psychosis right now, but we've seen interesting signals in other areas, which I'll show in a moment. And this has good drug-like properties. We know we're getting into the brain. We knew we're having an effect. And we are in full flight in a phase one study and that's progressing well and very consistently with what we've been able to demonstrate in animals so i don't expect anyone in this room to be able to read this chart but what it is essentially starting to show is it gives a flavor of some of the therapeutic areas that we've started to characterize our kcc2 direct activators in because the literature had always suggested kcc 2 would be interesting in pain and in epilepsy and we are indeed seeing signals there. But when you start to look more deeply, which we did starting to scratch the surface a couple years ago, KCC2 is implicated in many conditions and symptoms beyond that, including psychosis, anxiety, stress, areas like Rett syndrome, in addition to a number of developmental epileptic encephalopathies and more. So there's a lot of data that we have been building. The most robust data is in psychosis which is where we're trialing, where we intend to trial OV471 in the very near future. So where we are at the moment, we're running a phase one study that is progressing quite well. We've gone from SAD into the MAD program. We expect to finish that up around the end of Q1 of next year, 2027. We also are looking at exploratory electrophysiology in that study and hope to be able to demonstrate a signal, which would be quite exciting. Very soon, we will trigger a translational study called a ketamine challenge, And that study will essentially help us establish neuroactivity, neuroactility on mechanism associated with KCC2, so inhibition or GABAergic activity. And it has a very broad battery of biomarkers that may give us a predictive read-through to the clinical effect of OV4071 or KCC1 in a patient population, which would be great to get out of a phase one study. And it allows us to start to tick and tie the types of information we've now seen from more than 40 psychosis animal models to what we may predict to see in humans. And we're using a battery of very well-validated biomarkers using EEG and ERP. These are well-established in the field. So that would be incredibly exciting. And we intend to start a phase two acute schizophrenia study around the middle of next year. And why we chose schizophrenia is we know that KCC2 is highly relevant to a number of symptoms associated with schizophrenia. Specifically, when you look at post-mortem tissues of people who are living with schizophrenia, we see that there's been reduced KCC1 expression in the prefrontal cortex. And essentially, when we look at the post-Mortem, when you don't have the breaking system or inhibition working in your prefrontAL cortex, what schizophrenics experience essentially is an excitatory or glutamatergic storm leads to too much dopamine and striatum and drives a number of symptoms, positive symptoms. These pathways also mediate the negative symptoms of schizophrenia and cognition. So KCC2 is impacted in a number of different ways, and we have very good data in many animal models at this point that have given us conviction that the early signals we saw here may indeed be both profound but also therapeutic. And I will be the first to say We didn't start working on KCC2 because we intended to go into psychiatric applications. But at this point, the armamentarium of evidence is so profound, it's unignorable. It can't be ignored by me and the team. And one of the first models, I should take a step back. Psychiatric models are not seizure models or different types of cancer models. We don't trust psych models the same way we put faith in some of the other indications that we do. So the way around that is we look at disease models that replicate the type of biology that we're trying to solve for. So can we make the target dysfunctional or reduce its expression? Can we look a genetic models of disease? And we try to look at this every way that we can, as close to a 360-degree view as animal studies can take us, while we also progress in humans to make sure that if we're seeing signs of symptom amelioration, we really believe it. So this was one of the first studies that we conducted that really gave us that conviction. This is a stimulant model. It's meant to evoke the positive symptoms of psychosis. It's obviously not as complex as someone who's living with schizophrenia. But what we saw immediately was a dose-dependent response associated with OV4071. And what was really exciting to us in terms of reducing the hyperlocomotion, but what's unique to KCC2, unlike so many other psychiatric medicines we see that just kind of blast and dampen the CNS, what KCC2 direct activation appears to be doing is basically rescuing the symptom but not sedating the animals and this is also consistent with what we're seeing in humans so it's essentially returning the animal and humans back to your typical physiological state not overdoing it right we're trying to hit that Goldilocks place and when we look at and some of the animal models that we run, again, because I don't trust a stimulant model. It's the same thing as the complexity of someone living with a psychosis condition. We also look at the underlying biology and we look to see, okay, well, if we're reducing some of the upstream excitatory challenges that drive the symptoms of something like schizophrenia, are we seeing that actually change the downstream impacts? And indeed we are. This was a model that essentially was showing we reduced levels of dopamine in the striatum consistent with what we believed the mechanism of action was doing upstream. So these are positive symptom studies and very encouraging. And we've run these many fold over and we're seeing, even if we restore KCC2 activation by 50% in the prefrontal cortex, a profound rescue, both of uncognitive batteries, as well as behavioral batteries. We've also run negative symptom models. This again, it's like the holy grail for psychiatric indications and psychoses. No drug has really been able to deliver on positive, negative, and cognitive symptoms. KCC2 direct activation appears to be doing it. This is basically a model where you induce asociability in the animal. And when we give OV4071, again, we see both a rescue of typical physiological interactions and doing so in a way that's not sedating to the animal, and again, highly significant. And finally, because you've heard all my provisos of not trusting psych models as being a perfect proxy for the complexity of the human condition, we also try to run our drug against the best-in-class reference drugs. So in schizophrenia, clozapine, or risperidone, as this slide is showing, or cobenfi in the middle. And what we've seen when we run genetic models of schizophrenia that have the same symptoms that the broad schizophrenia population has, we've essentially seen that KCC2 outperforms reference drugs, both on various forms of cognition. These are well-proven batteries. These are hard to see in the back of the room, but different batteries for working memory and task switching. So very exciting. Our plan is acute schizophrenia for our phase two program, and we're looking at the positive symptoms primarily because those are the hardest endpoints to be able, hardest in terms of concrete and demonstrable endpoints for us to pursue. But the opportunity for KCC2 and psychosis appears to be possibly much bigger and possibly the triad of positive, negative, and cognitive improvement. Excitingly, we have translational biomarkers that we've been able to establish on EEG, both in genetic models of disease as well as in wild-type or natural animals. On the left is wild-type animals. On the right is a genetic model of Rett syndrome. It's seen to be a proxy for Rett syndrom. But excitingly, when we use these models and use our drug, we see, again, pretty rapid response of our drug. But we're also seeing modulation on EEG, which is consistent with GABAergic inhibition. So, again a restoration of the breaking system in the brain or inhibition in the brain working as it should. So we are very excited by this molecule. We're doing work to have in our discovery engine further candidates and backups some follow-ons associated with this, because the opportunity of drugging and unlocking KCC2, I believe, may be the next PD-1 of the brain. And we're trying to be thoughtful in terms of how we prosecute it. And that means a lot of work in the next two years. So this gives you a sense of just the activity that our team at Ovid has ongoing. So starting at the top, as I mentioned, we're in full flight with the Phase 2 Focal Epilepsy Program in Adults. That's, again, OV329. We're guiding that that will read out in the second half of next year, 2027. Very soon, we're going to be getting an answer on our open-label study, which is a photosensitivity study for the doses that we're characterizing in the clinic for 329. So that's now a matter of a few months away. Our pediatric formulation of OV329 has progressed well. It's coming online. We're initiating our study in children with tuberous sclerosis complex at the end of this year. That will also be an open-labels safety signal finding study, and we'll confirm our pediatric dosing. That will gate a study in infantile spasms that we intend to start next year. And then for KCC2, we are in the playoffs and hopefully headed to the Super Bowl with this. So we're in the phase one study right now. That's progressing well. We expect that'll end around Q1 of 2027. And we expect to trigger the ketamine challenge reasonably soon. And we also expect that that will be concluding around the end of the first quarter of 2026. So lots of work underway. That will be followed, hopefully, by an acute schizophrenia program, phase two program thereafter, though we think the opportunity with KCC2 is far bigger than schizophrenia, but we think it's a good proof of concept. So I'll pause there. Thank you for your time and attention.
- Company
- OVID THERAPEUTICS INC
- Keywords
- OVID THERAPEUTICS INC